-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123

Benzinga·08/26/2026 12:38:52
Listen to the news
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.